#ESC26: Arrowhead claims safety edge over Ionis as triglyceride battle draws closer

Phase 3positiveRedemploPositive

AI Analysis

Summary

Arrowhead's RNA interference drug Redemplo demonstrated safety advantages and effectiveness in two late-stage trials for high triglycerides, positioning it competitively against Ionis Pharmaceuticals' offerings in the market.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

Redemplo showed safety advantages and effectiveness in late-stage trials for high triglycerides

Importance:7/10

Sentiment:

0.65

RNA interferenceRNAitriglycerideslate-stage trialssafety profileESC26 conference

Related Companies

$IONS

Read the original article

Published by Endpoints News on August 30, 2026 3:40 PM

Read Original